



Iowa Department of Human Services

Terry E. Branstad
Governor

Kim Reynolds
Lt. Governor

Charles M. Palmer
Director

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

April 5, 2017

Location: Iowa Medicaid Enterprise
100 Army Post Road
Des Moines, Iowa, 50315
Rooms 128, 129, 130, 131

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of the Minutes
 - b) DHS Recommendation Letter – February 2017
 - c) Follow-Up from Previous Meeting(s)
 - i. MCO Lock-In Programs
 - ii. Synagis Claims
3. IME Pharmacy Update
4. Fee-for-Service Program Prevalence Report Summary
5. MCO Prevalence Report Summary and Updates
 - a) United Healthcare Community Plan
 - b) AmeriHealth Caritas Iowa
 - c) Amerigroup
6. Public Comment* (See Conflict of Interest Disclosure Form)
7. ProDUR Edits
 - a) Quantity Limits
 - i. Injectable Anticoagulant Quantity Limits – Impact
 - ii. Miscellaneous Quantity Limits – Second Review
 - b) EpiPen - Follow-up
8. Prior Authorization

- a) Deflazacort (Emflaza) – Initial Review
- b) Calcifediol (Rayaldee) – Initial Review
- c) Lesinurad (Zurampic) – Initial Review
- d) Sapropterin (Kuvan) – Initial Review
- e) High Dose Opioid (≥ 90 MME/day) – Second Review
- f) Insulin, Pre-Filled Pens – Second Review
- g) GLP-1 Agonist/Basal Insulin Combinations – Second Review
- h) Hepatitis C Treatments – Second Review
- i) Eteplirsen (Exondys 51) – Second Review
- j) Colchicine – Removal of Criteria – Second Review
- k) Lumacaftor/Ivacaftor (Orkambi) – Second Review

9. Miscellaneous

- a) DUR Digest Vol. 29, No. 3 – Initial Review
- b) MedWatch

10. Articles of Interest for Review

- a) First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update; found at <https://www.effectivehealthcare.ahrq.gov/ehc/products/615/2437/antipsychotics-children-update-report-170316.pdf>
- b) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease; found at <http://www.nejm.org/doi/full/10.1056/NEJMoa1615664#t=article>

11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

*****Next Meeting June 7, 2017***
Learning Resource Center
3550 Mills Civic Parkway, West Des Moines, IA**